Cargando…
Remdesivir: From Ebola to COVID-19
Human coronaviruses (HCoV) were discovered in the 1960s and were originally thought to cause only mild upper respiratory tract diseases in immunocompetent hosts. This view changed since the beginning of this century, with the 2002 SARS (severe acute respiratory syndrome) epidemic and the 2012 MERS (...
Autores principales: | Santoro, M. Gabriella, Carafoli, Ernesto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836944/ https://www.ncbi.nlm.nih.gov/pubmed/33388129 http://dx.doi.org/10.1016/j.bbrc.2020.11.043 |
Ejemplares similares
-
The journey of remdesivir: from Ebola to COVID-19
por: Pardo, Joe, et al.
Publicado: (2020) -
Remdesivir : d’Ebola à la Covid ?
por: Dalmat, Yann-Mickael
Publicado: (2021) -
Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola
por: Yan, Victoria C., et al.
Publicado: (2021) -
Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection
por: Carafoli, Ernesto
Publicado: (2021) -
Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus
por: Warren, Travis K., et al.
Publicado: (2021)